> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Inspire Sleep Apnea Device
- URL: https://www.fdaweb.com/regulatory-review-period-for-inspire-sleep-apnea-device/
- Published: 2017-10-23T12:00:00.000Z
- Updated: 2026-09-14T22:57:33.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139932

*Federal Register* notice: FDA has determined for patent extension purposes that the regulatory review period for Inspire’s Upper Airway Stimulation System is 2,002 days, and of this time, 1,653 days occurred during the testing phase and 349 days occurred during the approval phase. The product is indicated for treating a subset of patients with moderate to severe obstructive sleep apnea. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-10-23/pdf/2017-22897.pdf?ref=fdaweb.com).